Tyler Stone Wealth Management Has $224,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Tyler Stone Wealth Management lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 105.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,869 shares of the company’s stock after acquiring an additional 1,474 shares during the quarter. Tyler Stone Wealth Management’s holdings in AstraZeneca were worth $224,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AZN. Martin Investment Management LLC increased its position in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC increased its holdings in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning raised its position in AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after purchasing an additional 16,692 shares during the last quarter. TD Asset Management Inc lifted its holdings in AstraZeneca by 8.6% during the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after buying an additional 121,876 shares in the last quarter. Finally, Northcape Wealth Management LLC bought a new position in AstraZeneca in the 2nd quarter valued at $269,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of AZN opened at $64.79 on Tuesday. The business has a 50-day moving average of $76.61 and a 200-day moving average of $78.54. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company has a market capitalization of $200.89 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

Analyst Ratings Changes

A number of analysts recently commented on the company. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.